Sean Wharton

Nov 5, 2024 | healio.com | Scott Buzby |Richard Smith |Louis J. Aronne |Sean Wharton

You've successfully added Obesity in Endocrinology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Long-term tirzepatide reduced body weight and diabetes progression and was well tolerated in people with obesity and prediabetes.

Nov 4, 2024 | onlinelibrary.wiley.com | Sean Wharton |Mikhail Kosiborod |Elke Platz |Martina Brueckmann

What is already known? Antiobesity medications (AOMs) in conjunction with lifestyle changes are recommended for the treatment of obesity, but only a few AOMs are available to combat this highly prevalent and heterogenous disease. Survodutide is a dual glucagon and glucagon-like peptide-1 (GLP-1) receptor agonist under investigation for the treatment of obesity in people with BMI ≥ 30 kg/m2 or ≥27 kg/m2 with at least one obesity-related complication. What do these studies add?